ECOR

Company Overview — What Does electroCore, Inc. Do?

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey. electroCore, Inc. (ECOR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Daniel S. Goldberger and employs approximately 50 people. With a market capitalization of $53M, ECOR is one of the notable companies in the Healthcare sector.

electroCore, Inc. (ECOR) Stock Rating — Reduce (April 2026)

As of April 2026, electroCore, Inc. receives a Reduce rating with a composite score of 33.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ECOR ranks #2,329 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, electroCore, Inc. ranks #278 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ECOR Stock Price and 52-Week Range

electroCore, Inc. (ECOR) currently trades at $6.08. The stock lost $0.57 (8.6%) in the most recent trading session. The 52-week high for ECOR is $8.64, which means the stock is currently trading -29.6% from its annual peak. The 52-week low is $4.16, putting the stock 46.2% above its annual trough. Recent trading volume was 28K shares, suggesting relatively thin trading activity.

Is ECOR Overvalued or Undervalued? — Valuation Analysis

electroCore, Inc. (ECOR) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 1.85x, compared to 1.66x for the average Healthcare stock.

At current multiples, electroCore, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

electroCore, Inc. Profitability — ROE, Margins, and Quality Score

electroCore, Inc. (ECOR) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -337.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -71.9% versus the sector average of -33.1%.

On a margin basis, electroCore, Inc. reports gross margins of 85.5%, compared to 71.5% for the sector. The operating margin is -44.5% (sector: -66.1%). Net profit margin stands at -46.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 41.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ECOR Debt, Balance Sheet, and Financial Health

electroCore, Inc. has a debt-to-equity ratio of -608.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.38x, suggesting adequate working capital coverage. Total debt on the balance sheet is $8M. Cash and equivalents stand at $8M.

ECOR has a beta of 1.56, meaning it is more volatile than the broader market — a $10,000 investment in ECOR would be expected to move 56.4% more than the S&P 500 on any given day. The stability factor score for electroCore, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

electroCore, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, electroCore, Inc. reported revenue of $29M and earnings per share (EPS) of $-1.65. Net income for the quarter was $-13M. Gross margin was 85.5%. Operating income came in at $-13M.

In FY 2025, electroCore, Inc. reported revenue of $32M and earnings per share (EPS) of $-1.65. Net income for the quarter was $-14M. Gross margin was 86.8%. Revenue grew 27.2% year-over-year compared to FY 2024. Operating income came in at $-13M.

In Q3 2025, electroCore, Inc. reported revenue of $9M and earnings per share (EPS) of $-0.40. Net income for the quarter was $-3M. Gross margin was 86.0%. Revenue grew 32.6% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, electroCore, Inc. reported revenue of $7M and earnings per share (EPS) of $-0.44. Net income for the quarter was $-4M. Gross margin was 87.3%. Revenue grew 20.2% year-over-year compared to Q2 2024. Operating income came in at $-4M.

Over the past 8 quarters, electroCore, Inc. has demonstrated a growth trajectory, with revenue expanding from $6M to $29M. Investors analyzing ECOR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ECOR Dividend Yield and Income Analysis

electroCore, Inc. (ECOR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ECOR Momentum and Technical Analysis Profile

electroCore, Inc. (ECOR) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

ECOR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, electroCore, Inc. (ECOR) ranks #278 out of 838 stocks based on the Blank Capital composite score. This places ECOR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ECOR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ECOR vs S&P 500 (SPY) comparison to assess how electroCore, Inc. stacks up against the broader market across all factor dimensions.

ECOR Next Earnings Date

No upcoming earnings date has been announced for electroCore, Inc. (ECOR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ECOR? — Investment Thesis Summary

The quantitative profile for electroCore, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 27/100) increases portfolio risk.

In summary, electroCore, Inc. (ECOR) earns a Reduce rating with a composite score of 33.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ECOR stock.

Related Resources for ECOR Investors

Explore more research and tools: ECOR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ECOR head-to-head with peers: ECOR vs AZN, ECOR vs SLGL, ECOR vs VMD.